植入式鞘内镇痛泵因电池耗竭更换新泵1例
摘要
<正>吗啡鞘内给药可直接作用于脊髓阿片受体,发挥镇痛作用,其镇痛效价是口服吗啡的300倍~([1])。研究表明,持续鞘内镇痛可降低病人疼痛评分,同时减轻全身用药引起的诸多不良反应~([2])。美国食品药品监督管理局(The Food and Drug Administration,
引文
[1]韩济生,樊碧发.疼痛学[M].北京,北京大学医学出版社,2012,251-256.
[2]Robert B,Nagy M.Intrathecal pain pumps:indications patient selection,techniques,and outcomes[J].Neurosurg Clin N Am,2014,25:735-742.
[3]章沿锋,杨旖欣,冯智英.鞘内药物输注系统植入术适应证和药物选择的进展[J].中国疼痛医学杂志2018,24(10):723-728.
[4]Hayek SM,Hanes MC.Intrathecal therapy for chronic pain:current trends and future needs[J].Curr Pain Headache Rep,2014,18:388.
[5]Mueller-Schwefe G,Hassenbusch SJ,Reig E.Cost effectiveness of intrathecal therapy for pain[J].Neuromodulation,1999,2:77-87.
[6]Sayed D,Monroe F,Orr WN,et al.Retrospective Analysis of Intrathecal Drug Delivery:Outcomes,Efficacy,and Risk for Cancer-Related Pain at a High Volume Academic Medical Center[J].Neuromodulation,2018,21:660-664.
[7]Duarte RV,Lambe T,Raphael JH,et al.Intrathecal Drug Delivery Systems for the Management of Chronic Noncancer Pain:A Systematic Review of Economic Evaluations[J].Pain Pract,2018,18:666-686.
[8]Rainov NG,Buchser E.Making a case for programmable pumps over fixed rate pumps for the management of fluctuations in chronic pain and spasticity:a literature review[J].Neuromodulation,2002,5:89-99.
[9]Konrad PE,Huffman JM,Stearns LM,et al.Intrathecal Drug Delivery Systems(IDDS):The Implantable Systems Performance Registry(ISPR)[J].Neuromodulation,2016,19:848-856.
[10]Bolash R,Udeh B,Saweris Y,et al.Longevity and cost of implantable intrathecal drug delivery systems for chronic pain management:a retrospective analysis of365 patients[J].Neuromodulation,2015,18:150-155;discussion 155-156.
[11]Blount JP,Remley KB,Yue SK,et al.Intrathecal granuloma complicating chronic spinal infusion of morphine:Report of three cases[J].J Neurosurg,1996,84:272-276.
[12]Langsam A.Spinal Cord Compression by Catheter Granulomas in High-dose Intrathecal Morphine Therapy:Case Report[J].Neurosurgery,1999,44:689-691.
[13]Kratzsch T,Stienen MN,Reck T,et al.Catheter-tip Granulomas Associated with Intrathecal Drug Delivery-A Two-Center Experience Identifying 13 Cases[J]Pain Physician,2015,18:E831-840.
[14]Veizi IE,Hayek SM,Hanes M,et al.Primary Hydromorphone-Related Intrathecal Catheter Tip Granulomas:Is There a Role for Dose and Concentration?[J].Neuromodulation,2016,19:760-769.
[15]Chen M,Zhang X,Xu H,et al.Inhibitory effect of spinal mGlu5 receptor antisense oligonucleotide on the up-regulated expression of spinal G protein associated with chronic morphine treatment[J].Eur J Pharmacol,2014,723:253-258.
[16]Huang BQ,Hong Y.[Involvement of adrenomedullin in the pathogenesis of inflammatory pain and morphine tolerance[J].Sheng Li Xue Bao,2015,67:431-436.
[17]马霞青,许涛,江伟.P2X3受体的上调参与大鼠吗啡耐受的发生[J].中国疼痛医学杂志,2015,21(3):172-176.
[18]赵诗雯,田学愎.吗啡耐受的形成机制及治疗进展[J].中国疼痛医学杂志,2017,23(3):210-214.
[2]Robert B,Nagy M.Intrathecal pain pumps:indications patient selection,techniques,and outcomes[J].Neurosurg Clin N Am,2014,25:735-742.
[3]章沿锋,杨旖欣,冯智英.鞘内药物输注系统植入术适应证和药物选择的进展[J].中国疼痛医学杂志2018,24(10):723-728.
[4]Hayek SM,Hanes MC.Intrathecal therapy for chronic pain:current trends and future needs[J].Curr Pain Headache Rep,2014,18:388.
[5]Mueller-Schwefe G,Hassenbusch SJ,Reig E.Cost effectiveness of intrathecal therapy for pain[J].Neuromodulation,1999,2:77-87.
[6]Sayed D,Monroe F,Orr WN,et al.Retrospective Analysis of Intrathecal Drug Delivery:Outcomes,Efficacy,and Risk for Cancer-Related Pain at a High Volume Academic Medical Center[J].Neuromodulation,2018,21:660-664.
[7]Duarte RV,Lambe T,Raphael JH,et al.Intrathecal Drug Delivery Systems for the Management of Chronic Noncancer Pain:A Systematic Review of Economic Evaluations[J].Pain Pract,2018,18:666-686.
[8]Rainov NG,Buchser E.Making a case for programmable pumps over fixed rate pumps for the management of fluctuations in chronic pain and spasticity:a literature review[J].Neuromodulation,2002,5:89-99.
[9]Konrad PE,Huffman JM,Stearns LM,et al.Intrathecal Drug Delivery Systems(IDDS):The Implantable Systems Performance Registry(ISPR)[J].Neuromodulation,2016,19:848-856.
[10]Bolash R,Udeh B,Saweris Y,et al.Longevity and cost of implantable intrathecal drug delivery systems for chronic pain management:a retrospective analysis of365 patients[J].Neuromodulation,2015,18:150-155;discussion 155-156.
[11]Blount JP,Remley KB,Yue SK,et al.Intrathecal granuloma complicating chronic spinal infusion of morphine:Report of three cases[J].J Neurosurg,1996,84:272-276.
[12]Langsam A.Spinal Cord Compression by Catheter Granulomas in High-dose Intrathecal Morphine Therapy:Case Report[J].Neurosurgery,1999,44:689-691.
[13]Kratzsch T,Stienen MN,Reck T,et al.Catheter-tip Granulomas Associated with Intrathecal Drug Delivery-A Two-Center Experience Identifying 13 Cases[J]Pain Physician,2015,18:E831-840.
[14]Veizi IE,Hayek SM,Hanes M,et al.Primary Hydromorphone-Related Intrathecal Catheter Tip Granulomas:Is There a Role for Dose and Concentration?[J].Neuromodulation,2016,19:760-769.
[15]Chen M,Zhang X,Xu H,et al.Inhibitory effect of spinal mGlu5 receptor antisense oligonucleotide on the up-regulated expression of spinal G protein associated with chronic morphine treatment[J].Eur J Pharmacol,2014,723:253-258.
[16]Huang BQ,Hong Y.[Involvement of adrenomedullin in the pathogenesis of inflammatory pain and morphine tolerance[J].Sheng Li Xue Bao,2015,67:431-436.
[17]马霞青,许涛,江伟.P2X3受体的上调参与大鼠吗啡耐受的发生[J].中国疼痛医学杂志,2015,21(3):172-176.
[18]赵诗雯,田学愎.吗啡耐受的形成机制及治疗进展[J].中国疼痛医学杂志,2017,23(3):210-214.